SCHEMBL9975704

SCHEMBL9975704

CC1CCC(C2=C(c3cc(-c4ccccc4)sc3C(=O)O)CCN(CCc3ccccc3)C2)CC1

nearest known ligand 0.41

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.41
PTPN2 P17706 2/20 0.37
PTPN1 P18031 2/20 0.37
SIGMAR1 Q99720 1/20 0.37
CHRM5 P08912 5/20 0.37
CHRM1 P11229 5/20 0.37
CHRM2 P08172 4/20 0.36
CHRM4 P08173 4/20 0.36
CHRM3 P20309 4/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
CCR3 P51677 1/20 0.36
PRCP P42785 1/20 0.35
HTR2A P28223 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9975684 0.96 ALDH1A1 (0.40) ACHEPTPN2PTPN1SIGMAR1CHRM5
SCHEMBL9975662 0.95 SIGMAR1 (0.42) ACHEPTPN2PTPN1SIGMAR1CHRM5
SCHEMBL9975717 0.92 ACHE (0.38) ACHESIGMAR1CHRM5CHRM1CHRM2
SCHEMBL10364959 0.92 CHRM3 (0.36) SIGMAR1CHRM5CHRM1CHRM2CHRM4
SCHEMBL9975674 0.92 ALDH1A1 (0.36) CHRM5CHRM1CHRM2CHRM4CHRM3
SCHEMBL9975819 0.91 CHRM2 (0.34) CHRM5CHRM1CHRM2CHRM4CHRM3
SCHEMBL9975823 0.91 CHRM5 (0.42) CHRM5CHRM1CHRM2CHRM4CHRM3
SCHEMBL9941488 0.90 ALDH1A1 (0.38) CHRM5CHRM1CHRM2CHRM4CHRM3
SCHEMBL10323778 0.90 CHRM5 (0.35) PTPN2PTPN1SIGMAR1CHRM5CHRM1
SCHEMBL9941790 0.90 SIGMAR1 (0.37) SIGMAR1CHRM5CHRM1CHRM2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10426762-B2 Inhibitors of hepatitis C virus polymerase COCRYSTAL PHARMA, INC. (US) 2019-10-01 US disclosed
US-20170273962-A1 Inhibitors of Hepatitis C Virus Polymerase COCRYSTAL PHARMA, INC. 2017-09-28 US disclosed
US-20170273962-A1 Inhibitors of Hepatitis C Virus Polymerase COCRYSTAL PHARMA, INC. 2017-09-28 US disclosed
US-9707215-B2 Inhibitors of hepatitis C virus polymerase COCRYSTAL, DISCOVERY, INC. (US) 2017-07-18 US disclosed
US-9707215-B2 Inhibitors of hepatitis C virus polymerase COCRYSTAL, DISCOVERY, INC. (US) 2017-07-18 US disclosed
US-20150182514-A1 INHIBITORS OF HEPATITIS C VIRUS POLYMERASE COCRYSTAL PHARMA, INC. 2015-07-02 US disclosed
US-20150182514-A1 INHIBITORS OF HEPATITIS C VIRUS POLYMERASE COCRYSTAL PHARMA, INC. 2015-07-02 US disclosed
US-20140322165-A1 INHIBITORS OF HEPATITIS C VIRUS POLYMERASE COCRYSTAL DISCOVERY INC (US) 2014-10-30 US disclosed
US-20140322165-A1 INHIBITORS OF HEPATITIS C VIRUS POLYMERASE COCRYSTAL DISCOVERY INC (US) 2014-10-30 US disclosed
US-20140322165-A1 INHIBITORS OF HEPATITIS C VIRUS POLYMERASE COCRYSTAL DISCOVERY INC (US) 2014-10-30 US disclosed
US-8771665-B2 Inhibitors of hepatitis C virus polymerase COCRYSTAL DISCOVERY, INC. (US) 2014-07-08 US disclosed
US-8771665-B2 Inhibitors of hepatitis C virus polymerase COCRYSTAL DISCOVERY, INC. (US) 2014-07-08 US disclosed
US-8771665-B2 Inhibitors of hepatitis C virus polymerase COCRYSTAL DISCOVERY, INC. (US) 2014-07-08 US disclosed
US-20120183496-A1 INHIBITORS OF HEPATITIS C VIRUS POLYMERASE COCRYSTAL DISCOVERY, INC. (US) 2012-07-19 US disclosed
US-20120183496-A1 INHIBITORS OF HEPATITIS C VIRUS POLYMERASE COCRYSTAL DISCOVERY, INC. (US) 2012-07-19 US disclosed
US-20120183496-A1 INHIBITORS OF HEPATITIS C VIRUS POLYMERASE COCRYSTAL DISCOVERY, INC. (US) 2012-07-19 US disclosed
WO-2012083105-A1 INHIBITORS OF HEPATITIS C VIRUS POLYMERASE COCRYSTAL DISCOVERY, INC. (US) 2012-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10426762-B2 Inhibitors of hepatitis C virus polymerase POLR2E, POLR2H, GTF3C3 ACHE 3716/4885PTPN2 1140/4885PTPN1 775/4885
US-20120183496-A1 INHIBITORS OF HEPATITIS C VIRUS POLYMERASE POLR2A, POLR2B, POLR2E ACHE 3955/4885PTPN2 1729/4885PTPN1 1270/4885
US-20150182514-A1 INHIBITORS OF HEPATITIS C VIRUS POLYMERASE POLR2E, POLR2H, GTF3C3 ACHE 3716/4885PTPN2 1140/4885PTPN1 775/4885
US-20170273962-A1 Inhibitors of Hepatitis C Virus Polymerase POLR2E, POLR2H, GTF3C3 ACHE 3716/4885PTPN2 1140/4885PTPN1 775/4885
US-20140322165-A1 INHIBITORS OF HEPATITIS C VIRUS POLYMERASE POLR2A, POLR2B, POLR2E ACHE 3955/4885PTPN2 1729/4885PTPN1 1270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.